Preferential expression and immunogenicity of HIV-1 Tat fusion protein expressed in tomato plant

Transgenic Research

Volumn 19, Issue 5, 2010, Pages 889-895

  Cueno, Marni E ^a   Hibi, Yurina ^a   Karamatsu, Katsuo ^b   Yasutomi, Yasuhiro ^b   Imai, Kenichi ^a   Laurena, Antonio C ^c   Okamoto, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c UNIVERSITY OF THE PHILIPPINES LOS BAÑOS   (Philippines)

Author keywords

AIDS; Antibody response; Cellular immune response; HIV 1; Tat; Transgenic tomato

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; RECOMBINANT VACCINE; TRANSACTIVATOR PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CYTOTOXIC T LYMPHOCYTE; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; MOUSE; NUCLEOTIDE SEQUENCE; PHENOTYPE; POINT MUTATION; REGULATOR GENE; REPORTER GENE; TOMATO; TRANSGENIC PLANT; VACCINATION;

AIDS VACCINES; ANIMALS; BASE SEQUENCE; GENES, REPORTER; GENES, TAT; GENETIC VECTORS; HIV ANTIBODIES; HIV-1; IMMUNOGLOBULIN G; LYCOPERSICON ESCULENTUM; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PHENOTYPE; PLANTS, GENETICALLY MODIFIED; POINT MUTATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, SYNTHETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LYCOPERSICON ESCULENTUM; MUS;

EID: 77956488677     PISSN: 09628819     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11248-009-9358-9     Document Type: Article

References (35)

1. Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A et al (2001) The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 98: 1781-1786.
2. Barboric M, Peterlin BM (2005) A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation. PLoS Biol 3: 200-203.
3. Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, Teaberry V, West SM et al (2005) Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci USA 102: 4512-4517.
4. Bhatia P, Ashwath N (2004) Comparative performance of micropropagated and seed-grown tomato plants. Biologia Plantarum 48: 625-628.
5. Bieniasz PD, Grdina TA, Bogerd HP, Cullen BR (1998) Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO 17: 7056-7065.
6. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68: 6103-6110.
7. Emerman M, Malim MH (1998) HIV-1 regulatory/accessory genes: keys to unraveling viral and host cell biology. Science 280: 1880-1884.
8. Flexner C (2008) HIV drug development: the next 25 years. Nat Biotech 26(Suppl): s39-s46.
9. Fox JL (2007) Antivirals become a broader enterprise. Nat Biotech 25: 1395-1402.
10. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, Novitsky V et al (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
11. Goldstein G, Tribbick G, Manson K (2001) Two B cell epitopes of HIV-1 Tat proteins have limited antigenic polymorphism in geographically divers HIV-1 strains. Vaccine 19: 1738-1746.
12. Imai K, Nakatawa K, Kawai K, Hamano T, Mei N, Kasai H, Okamoto T (2005) Induction of OGG1 gene expression by HIV-1 Tat. J Biol Chem 280: 26701-26713.
13. Kanazawa S, Okamoto T, Peterlin BM (2000) Tat competes with CIITA for the binding to P-TEFb and blocks the exprression of MHC class II genes in HIV infection. Immunity 12: 61-70.
14. Karasev AV, Foulke S, Wellens C, Rich A, Shon KJ, Zwierzynski I, Hone D et al (2005) Plant-based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 23: 1875-1880.
15. Lilen SC, Imai K, Asamitsu K, Toshifumi T, Barzaga N, Okamoto T (2002) Inhibitory effects of IFN-[gamma] on HIV-1 replication in latently infected cells. Biochem Biophys Res Commun 291: 890-896.
16. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M, Sugimoto C et al (2004) Cytotoxic T lymphocytes-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199: 1709-1718.
17. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM (2000) M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164: 6166-6173.
18. Moore JP, Klasse PJ, Dolan MJ, Ahuja SK (2008) A step into darkness or light? Science 320: 753-755.
19. Morris CB, Thanawastien A, Sullivan DE, Clements JD (2001) Identification of a peptide capable of inducing an HIV-1 Tat specific CTL response. Vaccine 20: 12-15.
20. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EGT, Beatie T et al (2004) A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-spcific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85: 911-919.
21. Okamoto T (1995) Regulatory proteins of human immunodeficiency virus and therapy. In: Mohan P, Baba M (eds) Anti-AIDS development: challenges, strategies and prospects. Harwood Academic Publishers, Singapore, pp 117-123.
22. Okamoto T, Wong-Staal F (1986) Demonstration of virus-specific transcriptional activator(s) in cells infected with HTLV-III by an in vitro cell-free system. Cell 47: 29-35.
23. Okamoto H, Asamitsu K, Nishimura H, Kamatani N, Okamoto T (2000) Reciprocal modulation of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA. Biochem Biophys Res Commun 279: 494-499.
24. Ota S, Kanazawa S, Kobayashi M, Otsuka T, Okamoto T (2005) Establishment of a simple and quantitative immunospot assay for detecting anti-type II collagen antibody using infrared fluorescence imaging system (IFIS). J Immunol Methods 299: 189-198.
25. Potts M, Halperin DT, Kirby D, Swidler A, Marseille E, Klausner JD, Hearst N et al (2008) Reassessing HIV prevention. Science 320: 749-750.
26. Ramirez YJP, Tasciotti E, Gutierrez-Ortega A, Donayre AJ, Flores MTO, Giacca M, Lim MAG (2007) Fruit-specific expression of the human immunodeficiency virus type 1 Tat gene in tomato plants and its immunogenic potential in mice. Clin Vaccine Immunol 14: 685-692.
27. Shchelkunov SN, Salyaev RK, Pozdnyakov SG, Rekoslavskaya NI, Nesterov AE, Ryzhova TS, Sumstova VM et al (2006) Immunogenicity of a novel bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses. Biotechnol Lett 28: 959-967.
28. Sheeja TE, Mondal AB, Rathore RKS (2004) Efficient plantlet regeneration in tomato (Lycopersicon esculentum Mill.). Plant Tissue Cult 14: 45-53.
29. Takamura S, Matsuo K, Takebe Y, Yasutomi Y (2005) Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol 175: 2541-2547.
30. Tork S, Hatin I, Rousset J-P, Fabret C (2004) The major 5′ determinant in stop codon read-through involves two adjacent adenines. Nucleic Acids Res 32: 415-421.
31. Walker BD, Burton DR (2008) Toward and AIDS vaccine. Science 320: 760-764.
32. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14: 617-621.
33. Webster DE, Thomas MC, Pickering R, Whyte A, Dry IB, Gorry PR, Wesselingh SL (2005) Is there a role for plant-made vaccines in the prevention of HIV/AIDS? Immunol Cell Biol 83: 239-247.
34. WHO (2008) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. WHO Press, Spain.
35. Zahn LM, Hines PJ, Pennisi E, Travis J (2008) Green genes. Science 320: 465-478.